Venture Capital News: Breaking Venture Capital News, Comments and Articles. - Page: 4

11:42 EDT 19th April 2015 | BioPortfolio

Venture Capital News - Page: 4RSS

Read the latest Venture Capital News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Venture Capital.

Search or Follow Our Venture Capital - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Venture Capital - Page: 4 News.

Showing "venture capital" News Articles 76 to 100 of 7,600+

Wednesday 15th April 2015

Innocrin closes $28mm Series D round

Innocrin Pharmaceuticals Inc. (spun off from Viamet in 2014; developing small-molecule CYP17 lyase inhibitors for cancer) raised $28mm through its Series D round. Eschelman Ventures led (and takes a board seat) and was joined by existing investors No...

NEA raises $3.2B for two funds

New Enterprise Associates raised a total of $3.2 billion for two funds, including $2.8 billion for NEA 15 and $350 million for an adjunct fund, NEA 15 Opportunity Fund. The firm had targeted $2.5 billion for NEA 15 (see BioCentury Extra, Jan. 14).NEA...

Immune Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

NEW YORK, April 15, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc., (NASDAQ:IMNP) announced financial results for the fourth quarter and full year ended December 31, 2014. Immune filed its Annual Report on Form 10-K for fiscal year 2014 on Wednesday, April 15, 2015. "Over the last year, Immune has up-listed to the NASDAQ Capital Market and improved its capital structure to allow for timel...

AIT Bioscience Names Terri Pascarelli as New CEO

AIT Bioscience, LLC has appointed Terri Pascarelli, BS, MBA, as Chief Executive Officer and member, Board of Directors. Pascarelli’s appointment adds extensive business and entrepreneurial leadership to the company’s executive management team. AIT Bioscience is an innovative bioanalytical laboratory positioned uniquely at the interface of larg...

Echo Therapeutics, Inc. Announces 2014 Financial Results

ISELIN, N.J., April 15, 2015 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced financial results for the year ended December 31, 2014.  Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website a...

MEDIAN Technologies: 2014 Results

Order book doubles €11m at 31 December 2014, including €4.2m in firm orders and €6.8m in project awards(1), compared to €1.3m in firm orders at 31 December 2013 €4.4M order intake since 1 January 2015 of which €1.7m in firm orders including €0.4m in changes to existing orders an...

Janney starts Raptor Pharma at buy

Janney Capital Markets has launched coverage of Raptor Pharmaceuticals (NASDAQ:RPTP) with a “buy” rating and a fair value estimate of $16. The stock closed at $10.58 on Tuesday. Raptor is focused on developing and commercializing therapies for rare diseases. The company has PROCYSBI (RP103) currently approved in the U.S. and EU to treat a rare […]

African Anti-hunger Drive Could Be Blown Off Track by Climate Change

Sir Gordon Conway, a professor of international development at Imperial College London, United Kingdom, and one of the world’s leading scholars on agricultural development, said while he believes donors are committed to ending hunger in Africa, he worries that climate change could derail even the best of plans. “I think climate change is the biggest threat, particularly in Africa,” he said d...

Historic Senate Vote Provides Medical Liability Protections, Says Texas Alliance For Patient Access

AUSTIN, Texas, April 15, 2015 /PRNewswire-USNewswire/ -- Last night the U.S. Senate passed a bill that forbids federal quality-of-care and payment guidelines for Medicare, Medicaid and the Affordable Care Act to be used in medical liability lawsuits. The so-called "doc fix" bill marks the first time Congress has ever passed medical liability protections. The standard of care language is in ...

Scanadu and Zensor Join Forces to Form Team Scanadu/Intelesens in Quest for $10 Million Qualcomm Tricorder XPRIZE

NASA Ames Research Center – Scanadu Inc., the Silicon Valley-based medtech company, today announced that Qualcomm Tricorder XPRIZE finalist teams Scanadu, led by Walter de Brouwer, CEO of Scanadu, and zensor, led by Jim McLaughlin, CTO of Intelesens and Director at NIBEC - University of Ulster, have joined forces to create Team Scanadu/Intelesens. The mo...

Syros Pharmaceuticals to Present New Data from its Gene Control Platform in AML and Breast Cancer at AACR Annual Meeting 2015

- Research demonstrates how the comprehensive mapping of gene regulatory regions can illuminate clinically relevant subtypes and new therapeutic targets - Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that it will present two posters at the

Benchling Launches Cloud Platform to Accelerate Life Science R&D

Company raises $5M from Andreessen Horowitz and Thrive Capital to scale up commercial operations Benchling, Inc., a leading developer of cloud-based tools for life science, today announced the launch of its new platform which accelerates R&D by tracking experiment details, facilitating collaboration, and streamlining data analysis. The company also...

Healthcare Realty Trust Announces Senior Unsecured Note Offering

NASHVILLE, Tenn., April 15, 2015 /PRNewswire/ -- Healthcare Realty Trust Incorporated (NYSE: HR) today announced that it intends to offer, subject to market and other conditions, ten-year senior unsecured notes through an underwritten public offering. The Company expects to apply the net proceeds from the offering towards the redemption of the Company's 6.50% senior unsecured notes due 2017....

Insignia Capital Group Acquires Metanexgen

WALNUT CREEK, Calif., April 15, 2015 /PRNewswire/ -- Insignia Capital Group today announced the acquisition of metanexgen from DFW Capital Partners and the original Company founders.  Terms of the transaction were not disclosed. Based in Bensalem, PA, metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical dev...

SQI Delivers Sqidlite System to Global Pharmaceutical Customer

TORONTO, April 15, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), today announced the delivery and installation of a sqidlite™ system under the terms of an agreement with a top tier global pharmaceutical customer. As...

Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy

DUBLIN, April 15, 2015 /PRNewswire/ -- Heart Metabolics Limited, a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced that it has received an agreement letter from the U.S. Food and Drug Administration (FDA) related to the company's proposed Phase 3 trial Special Protocol Assessment (SPA) request. The FDA has a...

InspireMD Announces Completion of Sales Restructuring Program

BOSTON, April 15, 2015 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced the completion of its sales restructuring program which began on January 4, 2015. The restructuring was implemented to conserve capital and to align the organization to a new commercial strategy built on third party ...

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis

The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with Site Initiation and Patient Recruitment VANCOUVER, April 15, 2015 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has received approval from the...

New Website Launched by Leading Healthcare Staffing Agency Aureus Medical

The website of leading medical staffing agency Aureus Medical has undergone a redesign. With a new contemporary look, simplified navigation, and streamlined content, the company, which places healthcare professionals in travel nursing jobs, physical therapy jobs, and medical careers in other allied health fields, has improved its site to enhance the user experience. Omaha, NE (PRWEB) April 15, 201...

Chongqing Lummy Pharma In-licenses China Rights to Cancer Immunotherapy

Chongqing Lummy Pharma in-licensed greater China rights to Arcelis®, a cancer immunotherapy platform developed by Argos Therapeutics of North Carolina. Yesterday, Lummy announced it had invested in a $50 million China Fund with TVM Capital for in...

Medical Equipment Monthly Deals Analysis: January 2015 - M&A and Investment Trends

Recently added to the BioPortfolio report store, Medical Equipment Monthly Deals Analysis: January 2015 - M&A and Investment Trends is a new report from GlobalData published on 2015-03-15. This 81-page report is available in PDF from $1000. Medical Equipment Monthly Deals Analysis: January 2015 - M&A and Investment Trends Summary GlobalData's “Medical Equipment Monthly Deals Analysis: Janu...

Medical Equipment Monthly Deals Analysis: February 2015 - M&A and Investment Trends

Recently added to the BioPortfolio report store, Medical Equipment Monthly Deals Analysis: February 2015 - M&A and Investment Trends is a new report from GlobalData published on 2015-03-15. This 87-page report is available in PDF from $1000. Medical Equipment Monthly Deals Analysis: February 2015 - M&A and Investment Trends Summary GlobalData's “Medical Equipment Monthly Deals Analysis: Fe...

Tuesday 14th April 2015

Atlas Genetics Enters Into Diagnostic Collaboration With a Major Pharmaceutical Company

BATH, England, April 15, 2015 /PRNewswire/ -- Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases. The io® system is a highly novel molecular diagnostic...

Report: Healthcare, consumer wellness account for 14 percent of VC deals in Q1

Wearable devices helped fuel an appetite for mobile healthcare and consumer health deals, according to a report by CB Insights tracking venture capital dealflow in the first quarter. These mobile...

Lummy Strikes First Deal Under VC Fund Investment

TVM Capital Life Science has established a new $50 million venture capital fund with investment from Chinese partner Lummy, which has already tapped the new vehicle for a licensing deal for an oncology dendritic vaccine.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks